Suramin: Effectiveness of analogues reveals structural features that are important for the potent trypanocidal activity of the drug.
Competition assay
Flow cytometry
Suramin analogues
Trypanocidal activity
Trypanosoma brucei
Journal
Experimental parasitology
ISSN: 1090-2449
Titre abrégé: Exp Parasitol
Pays: United States
ID NLM: 0370713
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
received:
14
12
2023
revised:
22
02
2024
accepted:
18
03
2024
medline:
22
3
2024
pubmed:
22
3
2024
entrez:
21
3
2024
Statut:
aheadofprint
Résumé
Suramin was the first effective drug for the treatment of human African sleeping sickness. Structural analogues of the trypanocide have previously been shown to be potent inhibitors of several enzymes. Therefore, four suramin analogues lacking the methyl group on the intermediate rings and with different regiochemistry of the naphthalenetrisulphonic acid groups and the phenyl rings were tested to establish whether they exhibited improved antiproliferative activity against bloodstream forms of Trypanosomes brucei compared to the parent compound. The four analogues exhibited low trypanocidal activity and weak inhibition of antitrypanosomal activity of suramin in competition experiments. This indicates that the strong trypanocidal activity of suramin is most likely due to the presence of methyl groups on its intermediate rings and to the specific regiochemistry of naphthalenetrisulphonic acid groups. These two structural features are also likely to be important for the inhibition mechanism of suramin because DNA distribution and nucleus/kinetoplast configuration analyses suggest that the analogues inhibit mitosis while suramin inhibits cytokinesis.
Identifiants
pubmed: 38513971
pii: S0014-4894(24)00047-X
doi: 10.1016/j.exppara.2024.108744
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108744Informations de copyright
Copyright © 2024. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors declare that there were no commercial or financial interests or any other conflicts of interest.